CRISPR THERAPEUTICS AG (CRSP) — insider trading
Health Care · NASDAQ
CRISPR THERAPEUTICS AG (CRSP) has 40 reported SEC Form 4 insider transactions in our data, including 8 open-market sales among the most recent 40 (latest 2026-10-19).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-19 | Kulkarni Samarth | Director, Officer (Chief Executive Officer) | Open-market sale | 47,837 | $49.78 | $2.38M | Form 4 |
| 2026-10-16 | Kulkarni Samarth | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 100,000 | — | — | Form 4 |
| 2026-10-16 | Kulkarni Samarth | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 100,000 | — | — | Form 4 |
| 2026-10-14 | George Simeon | Director | Option exercise / conversion (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-10-14 | George Simeon | Director | Open-market sale | 14,514 | $49.63 | $720.4K | Form 4 |
| 2026-10-14 | George Simeon | Director | Option exercise / conversion | 30,000 | $14.00 | $420.0K | Form 4 |
| 2026-10-14 | KASINGER JAMES R. | Officer (General Counsel and Secretary) | Open-market sale | 1,040 | $49.26 | $51.2K | Form 4 |
| 2026-10-14 | Kulkarni Samarth | Director, Officer (Chief Executive Officer) | Open-market sale | 4,098 | $49.26 | $201.9K | Form 4 |
| 2026-10-13 | KASINGER JAMES R. | Officer (General Counsel and Secretary) | Option exercise / conversion (derivative) | 2,113 | — | — | Form 4 |
| 2026-10-13 | KASINGER JAMES R. | Officer (General Counsel and Secretary) | Option exercise / conversion | 2,113 | — | — | Form 4 |
| 2026-10-13 | Kulkarni Samarth | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 8,333 | — | — | Form 4 |
| 2026-10-13 | Kulkarni Samarth | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 8,333 | — | — | Form 4 |
| 2026-10-06 | KASINGER JAMES R. | Officer (General Counsel and Secretary) | Option exercise / conversion (derivative) | 1,990 | — | $0 | Form 4 |
| 2026-10-06 | KASINGER JAMES R. | Officer (General Counsel and Secretary) | Open-market sale | 1,990 | $60.04 | $119.5K | Form 4 |
| 2026-10-06 | KASINGER JAMES R. | Officer (General Counsel and Secretary) | Option exercise / conversion | 1,990 | $13.62 | $27.1K | Form 4 |
| 2026-09-22 | KASINGER JAMES R. | Officer (General Counsel and Secretary) | Option exercise / conversion (derivative) | 10,400 | — | $0 | Form 4 |
| 2026-09-22 | KASINGER JAMES R. | Officer (General Counsel and Secretary) | Open-market sale | 10,400 | $60.24 | $626.5K | Form 4 |
| 2026-09-22 | KASINGER JAMES R. | Officer (General Counsel and Secretary) | Option exercise / conversion | 10,400 | $13.62 | $141.6K | Form 4 |
| 2026-09-17 | Behbahani Ali | Director | Option exercise / conversion (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-09-17 | Behbahani Ali | Director | Open-market sale | 13,679 | $57.09 | $780.9K | Form 4 |
| 2026-09-17 | Behbahani Ali | Director | Option exercise / conversion | 30,000 | $14.00 | $420.0K | Form 4 |
| 2026-08-07 | Prasad Raju | Officer (Chief Financial Officer) | Bona fide gift | 750 | — | $0 | Form 4 |
| 2026-06-05 | Treco Douglas A | Director | Grant / award / vesting (derivative) | 13,000 | — | $0 | Form 4 |
| 2026-06-05 | Rommel Christian | Director | Grant / award / vesting (derivative) | 13,000 | — | $0 | Form 4 |
| 2026-06-05 | Morrison Briggs | Director | Grant / award / vesting (derivative) | 13,000 | — | $0 | Form 4 |
| 2026-06-05 | Mahatme Sandesh | Director | Grant / award / vesting (derivative) | 13,000 | — | $0 | Form 4 |
| 2026-06-05 | High Katherine A | Director | Grant / award / vesting (derivative) | 13,000 | — | $0 | Form 4 |
| 2026-06-05 | Greene John | Director | Grant / award / vesting (derivative) | 13,000 | — | $0 | Form 4 |
| 2026-06-05 | Fleming Harold Edward | Director | Grant / award / vesting (derivative) | 13,000 | — | $0 | Form 4 |
| 2026-06-05 | Fardis Maria | Director | Grant / award / vesting (derivative) | 13,000 | — | $0 | Form 4 |
| 2026-06-05 | Behbahani Ali | Director | Grant / award / vesting (derivative) | 13,000 | — | $0 | Form 4 |
| 2026-06-05 | George Simeon | Director | Grant / award / vesting (derivative) | 13,000 | — | $0 | Form 4 |
| 2026-05-29 | Prasad Raju | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 19,500 | — | $0 | Form 4 |
| 2026-05-29 | Patel Naimish | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 22,000 | — | $0 | Form 4 |
| 2026-05-29 | KASINGER JAMES R. | Officer (General Counsel and Secretary) | Grant / award / vesting (derivative) | 17,000 | — | $0 | Form 4 |
| 2026-05-29 | Patel Naimish | Officer (Chief Medical Officer) | Open-market sale | 3,786 | $55.62 | $210.6K | Form 4 |
| 2026-05-28 | Patel Naimish | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 10,000 | — | — | Form 4 |
| 2026-05-28 | Patel Naimish | Officer (Chief Medical Officer) | Option exercise / conversion | 10,000 | — | — | Form 4 |
| 2025-08-06 | Behbahani Ali | Director | Other acquisition or disposition | 15 | — | $0 | Form 4 |
| 2025-08-06 | Behbahani Ali | Director | Other acquisition or disposition | 60 | — | $0 | Form 4 |
Ask the chat about CRSP's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: CRISPR THERAPEUTICS AG (CRSP).
Last updated 2026-10-19 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.